KNOWLEDGE-BASED NEURAL NETWORK FOR LINE FLOW CONTINGENCY SELECTION AND RANKING

The Line flow Contingency Selection and Ranking (CS & R) is performed to rank the critical contingencies in order of their severity. An Artificial Neural Network based method for MW security assessment corresponding to line outage events have been reported by various authors in the literature. One way to provide an understanding of the behaviour of Neural Networks is to extract rules that can be provided to the user. The domain knowledge (fuzzy rules extracted from Multi-layer Perceptron model trained by Back Propagation algorithm) is integrated into a Neural Network for fast and accurate CS & R in an IEEE 14-bus system, for unknown load patterns and are found to be suitable for on-line applications at Energy Management Centers. The system user is provided with the capability to determine the set of conditions under which a line-outage is critical, and if critical, then how severe it is, thereby providing some degree of transparency of the ANN solution

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

10.1161/CIRCULATIONAHA.118.038840CIRCULATION1402103-11

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Background After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1.4-1.8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary syndrome and diabetes. However, the efficacy and safety of further reduction in LDL cholesterol with an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) after acute coronary syndrome is unknown. We aimed to explore this issue in a prespecified analysis of the ODYSSEY OUTCOMES trial of the PCSK9 inhibitor alirocumab, assessing its effects on cardiovascular outcomes by baseline glycaemic status, while also assessing its effects on glycaemic measures including risk of new-onset diabetes